Effect of application volume of ethanol-isopropyl myristate mixed solvent system on permeation of zidovudine and probenecid through rat skin

被引:10
作者
Jin, Y
Seki, T
Morimoto, Y
Juni, K
机构
[1] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan
[2] TTS Technol, Res Inst, Sakado, Saitama 3500295, Japan
关键词
ethanol-isopropyl myristate mixed system; probenecid; rat skin; skin permeation; zidovudine;
D O I
10.1081/DDC-100100344
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Permeation of zidovudine (AZT) and probenecid from an ethanol-isopropyl myristate (IPM) mixed system through rat skin was studied in a finite system. Several volume sizes of the ethanol-IPM mixed systems containing AZT and probenecid, both as suspensions, were applied on the skin of the hairless rat using a vertical glass cell, and the fractions of the drugs permeated in 8 hr Q(%,8hr) were determined. For the systems containing 40% ethanol, the Q(%,8hr) value decreased with the reduction of volume of the system applied, and the decreasing profile was similar to that calculated on the assumption that the permeability of the drug does not change with the volume of the sample applied. On the other hand, in the systems containing 10% or 20% ethanol, the Q(%,8hr) value showed a maximum when a specific volume of the sample was applied. Therefore, the effect of sample volume on the Q(%,8hr) value was different between the 40% ethanol-IPM system and the 10% or 20% ethanol-IPM system. Following pretreatment of the skin with 0.105 ml/cm(2) of drug-free 40% ethanol-IPM for 2 hr, several volume sizes of 10% ethanol-IPM systems containing the drugs were applied on the skin to explain why the different profiles were observed in the system containing 10% or 20% ethanol. The results for pretreated skin suggest that the amount of ethanol in the systems with low ethanol concentration and small application volume is too small to exert an effect that enhances permeation of the drugs. In those systems, the integrated effect of ethanol on the skin would be important for the enhancing effect. Total volume, as well as concentration, of an enhancer should be set precisely in designing an efficient transdermal delivery system.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 15 条
[1]   AN APPLICATION OF THE HYDRODYNAMIC PORE THEORY TO PERCUTANEOUS-ABSORPTION OF DRUGS [J].
HATANAKA, T ;
MANABE, E ;
SUGIBAYASHI, K ;
MORIMOTO, Y .
PHARMACEUTICAL RESEARCH, 1994, 11 (05) :654-658
[2]   EFFECT OF PROBENECID ON THE RENAL AND NONRENAL CLEARANCES OF ZIDOVUDINE AND ITS DISTRIBUTION INTO CEREBROSPINAL-FLUID IN THE RABBIT [J].
HEDAYA, MA ;
SAWCHUK, RJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (09) :716-722
[3]  
HOSOYA K, 1987, CHEM PHARM BULL, V35, P726
[4]  
Jin Y, 1996, DRUG DEV IND PHARM, V22, P653
[5]   RECTAL ABSORPTION OF ZIDOVUDINE [J].
KAWAGUCHI, T ;
HASEGAWA, T ;
JUNI, K ;
SEKI, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 77 (01) :71-74
[6]   PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF 3'-AZIDO-3'-DEOXYTHYMIDINE - A NOVEL PYRIMIDINE ANALOG WITH POTENTIAL APPLICATION FOR THE TREATMENT OF PATIENTS WITH AIDS AND RELATED DISEASES [J].
KLECKER, RW ;
COLLINS, JM ;
YARCHOAN, R ;
THOMAS, R ;
JENKINS, JF ;
BRODER, S ;
MYERS, CE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (04) :407-412
[7]   3'-AZIDO-3'-DEOXYTHYMIDINE (BW A509U) - AN ANTIVIRAL AGENT THAT INHIBITS THE INFECTIVITY AND CYTOPATHIC EFFECT OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-III LYMPHADENOPATHY-ASSOCIATED VIRUS INVITRO [J].
MITSUYA, H ;
WEINHOLD, KJ ;
FURMAN, PA ;
STCLAIR, MH ;
LEHRMAN, SN ;
GALLO, RC ;
BOLOGNESI, D ;
BARRY, DW ;
BRODER, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (20) :7096-7100
[8]   PHARMACOKINETIC EVALUATION OF DRUG-INTERACTIONS WITH ZIDOVUDINE .1. PROBENECID AND ZIDOVUDINE IN MONKEYS [J].
QIAN, MX ;
FINCO, TS ;
MEHTA, M ;
VISWANATHAN, CT ;
GALLO, JM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (11) :1007-1011
[9]   EFFECT AND MODE OF ACTION OF ALIPHATIC ESTERS ON THE INVITRO SKIN PERMEATION OF NICORANDIL [J].
SATO, K ;
SUGIBAYASHI, K ;
MORIMOTO, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 43 (1-2) :31-40
[10]  
SCHULTZ SG, 1980, BASIC PRINCIPLES MEM, P57